Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have been given an average rating of “Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.40.

BTAI has been the subject of several recent analyst reports. Zacks Investment Research cut shares of BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of BioXcel Therapeutics in a research note on Wednesday, December 12th.

Shares of BioXcel Therapeutics stock traded down $0.13 during trading on Friday, hitting $6.05. 43,283 shares of the company were exchanged, compared to its average volume of 375,180. BioXcel Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $14.79.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Friday, November 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.05). On average, analysts forecast that BioXcel Therapeutics will post -1.2 EPS for the current fiscal year.

In other news, Director Peter Mueller purchased 8,795 shares of BioXcel Therapeutics stock in a transaction that occurred on Friday, December 7th. The stock was acquired at an average price of $5.01 per share, for a total transaction of $44,062.95. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders purchased 19,152 shares of company stock valued at $95,778.

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning acquired a new position in BioXcel Therapeutics in the 3rd quarter valued at approximately $102,000. BlackRock Inc. acquired a new position in BioXcel Therapeutics in the 2nd quarter valued at approximately $137,000. Point72 Asset Management L.P. increased its stake in BioXcel Therapeutics by 10.7% in the 2nd quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after buying an additional 6,358 shares during the period. Finally, Artemis Investment Management LLP increased its stake in BioXcel Therapeutics by 1.3% in the 3rd quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock valued at $9,700,000 after buying an additional 16,358 shares during the period. Hedge funds and other institutional investors own 20.79% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.